Sign In

Stefan Frings

Global Head of Medical Affairs Roche Pharma Product Development

Professional Background

Stefan Frings is an esteemed expert in the pharmaceutical industry, with an impressive track record that showcases his significant contributions to medical affairs, strategy, and clinical operations. Throughout his extensive career at Roche, a global leader in pharmaceuticals, he has held numerous pivotal roles that highlight his expertise in oncology and medical affairs. As the current Global Head of Medical Affairs at Roche Pharma Product Development, Stefan has been at the forefront of advancing medical innovations that have the potential to change the lives of patients around the world.

Before taking on his current role, Stefan made substantial impacts as the Head of Strategy, Portfolio & Clinical Operations for Roche Pharma Research and Early Development. His strategic vision and operational acumen were instrumental in driving key initiatives and ensuring that Roche remained at the cutting edge of medical advancements. His leadership in medical affairs has been shaped by his previous roles, including as the Head of Medical Affairs for Roche Germany, where he established strong partnerships and executed effective medical strategies that drove the success of Roche’s products.

Over the years, Stefan has further solidified his reputation by taking on critical responsibilities as Global Head of Business Development and Licensing (BD&L) for Hematology, Oncology, and Cancer Immunotherapy. His extensive experience in managing complex global portfolios has made him a sought-after thought leader in the fields of oncology and immunotherapy, enhancing Roche’s competitive edge in these vital areas of healthcare. His work as the Global Head of Medical Affairs for Oncology at Roche further illustrates his deep commitment to quality patient care through innovative cancer treatment options.

Education and Achievements

Stefan’s journey in the medical field began with a focus on medicine at the University of Düsseldorf, where he earned his Doctor of Medicine degree. This rigorous academic background laid a solid foundation for his eventual decision to specialize in vascular surgery, leading him to obtain a Doctor of Philosophy from the same prestigious institution. His educational qualifications reflect his dedication to understanding complex medical concepts, which have undoubtedly contributed to his ability to make data-driven decisions at a corporate level.

Throughout his tenure at Roche, Stefan has held various leadership positions related to specific oncology products, significantly impacting the development and commercialization of Roche's therapeutics. As the Avastin Franchise Director and HER2 Franchise Director, he played a crucial role in strategy development and execution, leveraging his medical and operational expertise to optimize product lifecycle management and drive therapeutic success.

Moreover, Stefan's numerous roles—including Life Cycle Leader for Roche Oncology - Avastin, along with several positions focused on Xeloda and pertuzumab—demonstrate his comprehensive understanding of the oncology landscape and the importance of meticulous product management. His ability to collaborate across departments and lead diverse teams has been critical to achieving Roche's ambitious goals in product development and patient care.

Achievements

Stefan Frings has been pivotal in fostering innovation in oncology through medical affairs, ensuring that Roche remains a formidable leader in this competitive field. His strategic insights and ability to translate complex medical data into actionable strategies have been essential to the company's success. His contributions extend beyond operational excellence; they encompass a genuine commitment to improving patient outcomes and advancing the science of medicine.

As an influential figure in medical affairs at Roche, Stefan has promoted a culture of collaboration that enhances knowledge sharing and interdisciplinary cooperation. His leadership style, characterized by inclusivity and respect for diverse viewpoints, has helped inspire teams to navigate challenges effectively, driving the organization towards high levels of achievement.

Stefan's profound impact on the oncology sector, particularly in areas such as Hematology and Cancer Immunotherapy, showcases his expertise not only as a leader but also as a compassionate advocate for patients. He has consistently championed initiatives aimed at delivering effective treatment options while optimizing patient experience.

In summary, Stefan Frings exemplifies what it means to be a dedicated leader in the pharmaceutical industry. His journey, from his educational pursuits in medicine and philosophy to his strategic roles at Roche, underscores his unwavering commitment to excellence in medical affairs and patient care. With an impressive background that uniquely qualifies him to navigate the complexities of oncology, Stefan continues to make significant strides in advancing medical scie

Highlights

Mar 14 · linkedin

Writing from the International Experience Exchange with Patient Organizations (@IEEPO) from Zurich, Switzerland. At Roche, our goal is to harness evidence-based advocacy by embedding voices from those with lived experience to strengthen health systems and accelerate innovation.

Our extensive discussions with women are helping us to gain a much deeper understanding of the frustrations they face when they are trying to navigate our healthcare systems.

They are clear: they no longer want to wait on diagnoses; they want more support after diagnosis; they want easier access to care and treatment.

Our job is to make sure these voices are heard and the needs are met. At this year’s @IEEPO, we will be exploring how we all work together to make sure the perspectives of people living with conditions are systematically embedded within our healthcare systems.

A huge thank you to the IEEPO External Advisory Committee and IEEPO Core team for their unwavering dedication! And a special shoutout to our Patient Advocates - you inspire us every day! Together, we are making a difference in the lives of patients. Join the IEEPO community!

#HumanisingHealthcare #UHC #AccelerateAction

Rebecca Vermeulen, Ahmed Magdi, Elizabeth Park, Giuseppe De Carlo, Silvia Carter, Cláudia Echeverria, Rachel Scott, Annette Kuhnert, Natalie Suhr, Monica Ruoss

Apr 28 · linkedin

We're very proud to announce that Roche has been ranked 1st in the Corporate Reputation of Pharma 2022 survey by PatientView. This recognition by over 2,200 patient groups is a testament to our commitment to putting patient outcomes at the center of everything we do.

Thank you to all who participated. We are committed to continue listening to your needs to deliver on our promise of patient-centricity.

You can find the press release here 👉 http://spkl.io/60404ehUs

#StrongerTogether #patientcentricity

Related Questions

How did Stefan Frings develop his expertise in oncology within the pharmaceutical industry?
What innovative strategies has Stefan implemented during his time as Global Head of Medical Affairs at Roche?
In what ways has Stefan Frings contributed to the advancement of cancer immunotherapy research and development?
How has Stefan's education at the University of Düsseldorf influenced his career in medicine and pharmaceuticals?
What leadership qualities define Stefan Frings' approach to managing diverse teams in the medical affairs sector?
Stefan Frings
Add to my network

Location

Basel, Basel, Switzerland